MIDD In Early Oncology Clinical Development: Dose Optimization

Dose optimization has become an increasingly challenging, but necessary task as developers explore more next-generation oncology therapies and novel combinations. Find out how model-informed drug development (MIDD) can play an integral role in keeping vital oncology trials on track to deliver life-saving therapies to patients in need.

Get an inside look at:

Dose optimization and its challenges in novel modalities
Addressing dose optimization early in oncologic therapy development
How to anticipate and address worldwide regulatory hurdles
Using MIDD to quantitatively evaluate efficacy and safety
The future of early oncology development

Sign up to our content service and access now

Your company email address

Please select your industry: (max 1)

Opt In?

By you requesting this resource, you agree to our terms of use. All data is protected by our Privacy Notice. You can change your contact preferences here. If you have any further questions please get in contact.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
By clicking submit, you consent to allow Allucent to store and process the information submitted to provide you the content requested. They are subject to Allucent's Terms and Conditions.

MIDD In Early Oncology Clinical Development: Dose Optimization

Sign up to our content service and access now

Opt In?

Explore similar content

Resiliency and innovation - Navigating the current biotech landscape

HIV – Global Clinical Trial Landscape

Incorporating Digital Biomarkers & Endpoints Into Clinical Trials: Key Regulatory Considerations